GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min

Gilead Sciences cash flow statement 1990–2026

Gilead Sciences's free cash flow over the last twelve months was 13.78B USD: operating cash flow of 14.48B USD less 699.00M USD of capital spending. That is 44.5% of its revenue and 11.02 a share.

Operating cash flow Free cash flow

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Net income
4.61B8.51B480.00M5.67B4.59B6.20B123.00M5.36B5.46B4.64B13.49B
Depreciation and amortization
2.81B2.76B2.77B2.69B2.10B2.05B1.48B1.40B1.43B1.29B1.16B
Stock-based compensation
464.00M894.00M835.00M766.00M644.00M635.00M643.00M636.00M845.00M638.00M380.00M
Change in working capital
410.00M-3.95B-880.00M-2.30B-1.76B489.00M-1.64B-798.00M-939.00M5.11B1.55B
Change in receivables
231.00M-367.00M139.00M157.00M-406.00M313.00M-1.17B-218.00M480.00M754.00M1.19B
Change in inventory
-375.00M-1.04B-426.00M-842.00M-310.00M11.00M-195.00M-95.00M-310.00M-253.00M-488.00M
Change in payables
159.00M-132.00M290.00M-347.00M226.00M-118.00M80.00M-61.00M-39.00M-430.00M47.00M
Change in other working capital
395.00M-2.41B-883.00M-1.27B-1.27B283.00M-352.00M-424.00M-1.07B5.04B795.00M
Other non-cash items
6.10B1.64B9.47B2.15B5.05B2.13B7.77B4.64B1.32B304.00M594.00M
Operating cash flow
14.48B10.02B10.83B8.01B9.07B11.38B8.17B9.14B8.40B11.90B17.05B
Operating cash flow growth
+49.79%-7.47%+35.25%-11.75%-20.31%+39.37%-10.67%+8.86%-29.40%-30.20%-19.78%
Capital expenditure
-699.00M-563.00M-523.00M-585.00M-728.00M-579.00M-650.00M-825.00M-924.00M-590.00M-748.00M
Acquisitions
-628.00M-1.07B-4.84B-1.15B-1.80B-1.58B-25.74B-4.25B0.00-10.43B0.00
Purchases of investments
-1.40B-4.07B-736.00M-2.37B-1.94B-3.90B-20.77B-32.23B-10.39B-23.31B-25.98B
Sales and maturities of investments
—909.00M2.59B1.84B2.00B2.91B32.72B29.92B25.86B18.26B14.74B
Other investing
-8.55B3.00M58.00M0.00-1.00M19.00M-171.00M-434.00M-190.00M0.000.00
Investing cash flow
-10.66B-4.79B-3.45B-2.27B-2.47B-3.13B-14.62B-7.82B14.36B-16.07B-11.99B
Debt issued (repaid)
1.28B-1.79B1.49B-270.00M-1.50B-4.75B5.68B-2.75B-6.25B7.17B4.27B
Shares issued
294.00M408.00M422.00M232.00M309.00M169.00M256.00M209.00M289.00M234.00M208.00M
Share buybacks
-1.37B-1.92B-1.15B-1.00B-1.40B-546.00M-1.58B-1.75B-2.90B-954.00M-11.00B
Dividends paid
-4.10B-4.00B-3.92B-3.81B-3.71B-3.61B-3.45B-3.22B-2.97B-2.73B-2.46B
Other financing
-779.00M-440.00M-281.00M-278.00M-173.00M-145.00M-138.00M-122.00M-486.00M-330.00M-745.00M
Financing cash flow
-4.69B-7.75B-3.43B-5.13B-6.47B-8.88B770.00M-7.63B-12.32B3.39B-9.73B
Net change in cash
-890.00M-2.43B3.91B673.00M74.00M-659.00M-5.63B-6.31B10.35B-641.00M-4.62B
Free cash flow
13.78B9.46B10.31B7.42B8.34B10.81B7.52B8.32B7.48B11.31B16.30B
Free cash flow growth
+50.41%-8.24%+38.86%-11.06%-22.78%+43.72%-9.63%+11.28%-33.89%-30.62%-20.50%
Free cash flow margin
44.47%32.12%35.84%27.37%30.59%39.57%30.45%37.06%33.79%43.31%53.63%
Free cash flow per share
11.027.538.215.906.618.565.956.515.728.5712.00
Free cash flow per share growth
+51.20%-8.24%+39.19%-10.78%-22.78%+43.84%-8.63%+13.98%-33.33%-28.57%-10.96%
Interest paid
——951.00M891.00M907.00M979.00M951.00M982.00M1.07B1.04B885.00M
Income taxes paid
—0.002.78B3.99B3.14B2.51B2.64B1.79B3.20B3.34B2.44B

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Gilead Sciences's cash flow

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.